We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FLEX:NASDAQFlex Ltd. Analysis

Data as of 2026-09-05 - not real-time

$109.51

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Flex Ltd. is priced at $109.51, and its moving averages give no clean directional read — the structure is neutral. It has lost 7.6% over the past 30 days. RSI sits at 42.9, which reads as neutral, and MACD momentum is bearish. Recent trading has carved out support near $102.25 and resistance around $131.63.
On valuation the read is fair — earnings multiple of 42.4 versus a 33.2 sector average, above the peer group. Sell-side targets cluster 44.6% above the current quote. Revenue is growing at 20.6% on a 3.3% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 62.1%, a beta of 2.88 and a maximum drawdown of 36.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 1 out of 10.

Top Market Events

Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for its “Artisan...Third Point Management, a New York-based investment advisor, released its second-quarter 2026 investor letter.Yahoo Finance1monFlex Ltd. FLEX Outgrew the Fund’s Small-Cap Mandate on AI Data Center StrengthThe above button links...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading above the 200-day average of 94.84
  • MACD momentum is negative
  • 30-day price change of -7.6%

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 42.4 versus sector average of 33.2
  • Trading above the 200-day average of 94.84
  • Analyst targets imply +44.6% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 1/10

Key Factors

  • P/E of 42.4 versus sector average of 33.2
  • Analyst targets imply +44.6% versus the current price
  • Revenue growth of +20.6%

Key Metrics & Analysis

Financial Health

Revenue Growth20.60%
Profit Margin3.33%
P/E Ratio42.4
ROE18.38%
ROA4.42%
Debt/Equity107.82
P/B Ratio7.4
Op. Cash Flow$1.6B
Free Cash Flow$625.8M
Industry P/E33.2

Technical Analysis

TrendNeutral
RSI42.9
Support$102.25
Resistance$131.63
MA 20$114.71
MA 50$123.04
MA 200$94.84
MACDBearish
VolumeStable
Fear & Greed Index95.48

Valuation

Fair Value$41.20
Target Price$158.33
Upside/Downside44.58%
GradeFair
TypeGrowth

Risk Assessment

Beta2.88
Volatility62.07%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.